CBD 对帕金森病的潜在影响:最新概述。

IF 1.7 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Open Medicine Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI:10.1515/med-2024-1075
El Ghachi Hafida, Soulimani Rachid, Gamrani Halima, Kissani Najib
{"title":"CBD 对帕金森病的潜在影响:最新概述。","authors":"El Ghachi Hafida, Soulimani Rachid, Gamrani Halima, Kissani Najib","doi":"10.1515/med-2024-1075","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) is primarily known as a motor disorder; however, its debilitating non-motor symptoms have a significant impact on patients' quality of life. The current standard treatment, l-DOPA, is used to relieve motor symptoms, but prolonged use is often associated with severe side effects. This creates an urgent need for effective alternatives targeting both motor and non-motor symptoms.</p><p><strong>Objectives: </strong>Over the past decade, <i>Cannabis sativa</i> and its cannabinoids have been widely studied across various health conditions. Among these compounds, cannabidiol (CBD), a non-psychoactive component, is garnering growing interest due to its multi-targeted pleiotropic properties. This work aims to provide a comprehensive overview of CBD's efficacy in PD.</p><p><strong>Methods: </strong>This review compiles data on both motor and non-motor symptoms of PD, integrating results from preclinical animal studies and available clinical trials.</p><p><strong>Results: </strong>Preclinical research has demonstrated promising results regarding CBD's potential benefits in PD; however, the total number of clinical trials is limited (with only seven studies to date), making it difficult to draw definitive conclusions on its efficacy.</p><p><strong>Conclusions: </strong>While preclinical findings suggest that CBD may have therapeutic potential in PD, the limited number of clinical trials highlights the need for further research. This review emphasizes the gaps that need to be addressed in future studies to fully understand CBD's role in treating both motor and non-motor symptoms of PD.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"19 1","pages":"20241075"},"PeriodicalIF":1.7000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524397/pdf/","citationCount":"0","resultStr":"{\"title\":\"CBD's potential impact on Parkinson's disease: An updated overview.\",\"authors\":\"El Ghachi Hafida, Soulimani Rachid, Gamrani Halima, Kissani Najib\",\"doi\":\"10.1515/med-2024-1075\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Parkinson's disease (PD) is primarily known as a motor disorder; however, its debilitating non-motor symptoms have a significant impact on patients' quality of life. The current standard treatment, l-DOPA, is used to relieve motor symptoms, but prolonged use is often associated with severe side effects. This creates an urgent need for effective alternatives targeting both motor and non-motor symptoms.</p><p><strong>Objectives: </strong>Over the past decade, <i>Cannabis sativa</i> and its cannabinoids have been widely studied across various health conditions. Among these compounds, cannabidiol (CBD), a non-psychoactive component, is garnering growing interest due to its multi-targeted pleiotropic properties. This work aims to provide a comprehensive overview of CBD's efficacy in PD.</p><p><strong>Methods: </strong>This review compiles data on both motor and non-motor symptoms of PD, integrating results from preclinical animal studies and available clinical trials.</p><p><strong>Results: </strong>Preclinical research has demonstrated promising results regarding CBD's potential benefits in PD; however, the total number of clinical trials is limited (with only seven studies to date), making it difficult to draw definitive conclusions on its efficacy.</p><p><strong>Conclusions: </strong>While preclinical findings suggest that CBD may have therapeutic potential in PD, the limited number of clinical trials highlights the need for further research. This review emphasizes the gaps that need to be addressed in future studies to fully understand CBD's role in treating both motor and non-motor symptoms of PD.</p>\",\"PeriodicalId\":19715,\"journal\":{\"name\":\"Open Medicine\",\"volume\":\"19 1\",\"pages\":\"20241075\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524397/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1515/med-2024-1075\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2024-1075","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:帕金森病(Parkinson's disease,PD)主要是一种运动障碍,但其令人衰弱的非运动症状对患者的生活质量有很大影响。目前的标准疗法 l-DOPA 用于缓解运动症状,但长期使用往往会产生严重的副作用。因此,迫切需要针对运动症状和非运动症状的有效替代品:在过去十年中,人们对大麻及其大麻素进行了广泛研究,涉及各种健康状况。在这些化合物中,大麻二酚(CBD)是一种非精神活性成分,因其具有多靶点多效应特性而受到越来越多的关注。本研究旨在全面概述大麻二酚对帕金森病的疗效:本综述综合了临床前动物研究和现有临床试验的结果,汇编了有关帕金森病运动症状和非运动症状的数据:临床前研究已经证明了 CBD 对帕金森病的潜在益处;然而,临床试验的总数有限(迄今为止仅有七项研究),因此很难就其疗效得出明确结论:尽管临床前研究结果表明,CBD 可能对帕金森病有治疗潜力,但临床试验数量有限,这凸显了进一步研究的必要性。本综述强调了未来研究中需要解决的差距,以充分了解 CBD 在治疗帕金森病的运动和非运动症状方面的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
CBD's potential impact on Parkinson's disease: An updated overview.

Background: Parkinson's disease (PD) is primarily known as a motor disorder; however, its debilitating non-motor symptoms have a significant impact on patients' quality of life. The current standard treatment, l-DOPA, is used to relieve motor symptoms, but prolonged use is often associated with severe side effects. This creates an urgent need for effective alternatives targeting both motor and non-motor symptoms.

Objectives: Over the past decade, Cannabis sativa and its cannabinoids have been widely studied across various health conditions. Among these compounds, cannabidiol (CBD), a non-psychoactive component, is garnering growing interest due to its multi-targeted pleiotropic properties. This work aims to provide a comprehensive overview of CBD's efficacy in PD.

Methods: This review compiles data on both motor and non-motor symptoms of PD, integrating results from preclinical animal studies and available clinical trials.

Results: Preclinical research has demonstrated promising results regarding CBD's potential benefits in PD; however, the total number of clinical trials is limited (with only seven studies to date), making it difficult to draw definitive conclusions on its efficacy.

Conclusions: While preclinical findings suggest that CBD may have therapeutic potential in PD, the limited number of clinical trials highlights the need for further research. This review emphasizes the gaps that need to be addressed in future studies to fully understand CBD's role in treating both motor and non-motor symptoms of PD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Open Medicine
Open Medicine Medicine-General Medicine
CiteScore
3.00
自引率
0.00%
发文量
153
审稿时长
20 weeks
期刊介绍: Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信